gdc

Lymphoma

FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
FDA Approvals, News & UpdatesLymphoma
In July 2020, the FDA approved Monjuvi as a new treatment option for patients with diffuse large B-cell lymphoma whose disease progressed after receiving other therapies.
Tecartus First Gene Therapy FDA Approved for Patients with Mantle-Cell Lymphoma
FDA Approvals, News & UpdatesLymphoma
The FDA approved Tecartus as the first gene therapy (or CAR T-cell therapy) for patients with mantle-cell lymphoma, a rare type of non-Hodgkin lymphoma, that progressed after previous therapies.
Yescarta Leads to Long-Term Responses in  Patients with Advanced Follicular Lymphoma or Marginal-Zone Lymphoma
Lymphoma
A total of 80% of patients with relapsed (coming back) or refractory (not responding to therapy) slow-growing (indolent) non-Hodgkin lymphoma (NHL)—including patients with follicular lymphoma or marginal-zone lymphoma (MZL)—achieved a complete response (no sign of cancer) to Yescarta (axicabtagene ciloleucel), an anti-CD19 CAR T-cell therapy.
Keytruda New Standard of Care for Relapsed or Refractory Classical Hodgkin Lymphoma
Lymphoma
Treatment with the PD-1 inhibitor Keytruda (permbrolizumab) significantly extended progression-free survival (PFS) in patients with classical Hodgkin lymphoma compared with standard treatment with Adcetris (brentuximab vedotin), according to the results of the phase 3 KEYNOTE-204 clinical trial reported at the ASCO 2020 virtual annual meeting.
From the Brink of Death to the Top of a Mountain: The Magic of CAR T-Cell Immunotherapy
Patient StoriesImmunotherapyLymphoma
Laurie Adami chronicles her long fight with follicular lymphoma, including her run-in with 6 types of therapies. After losing all hope, she finally achieved complete remission with a new immunotherapy called CAR T-cell therapy, and then turned her sights on climbing Mt. Everest to raise money for cancer research.
Keytruda Immunotherapy Prolongs Survival in Patients with Relapsed or Refractory Hodgkin Lymphoma
ImmunotherapyLymphoma
This article discusses findings from a clinical trial showing that Keytruda prolongs the time without disease progression in patients with relapsed or refractory classical Hodgkin lymphoma compared with the current standard of therapy.
CONQUER Cam: A Spotlight on Brad Power
CONQUER CamLymphomaPatient Stories
Bradford Power took the credibility he had as a patient diagnosed with cancer and used it to fuel his purpose and mission of helping others navigate their cancer diagnosis and treatment.
7-Year-Old Lynden Raises Money for Cancer Research While Fighting Lymphoma
LymphomaPediatric Cancer
A year before Lynden was diagnosed with cancer, she cut off her hair and donated it to help kids with cancer. After her diagnosis, she launched a new project. She is just getting started, but so far she has raised more than $65,000 for pediatric cancer research.
Spreading Fun and Games
Humor & CancerPatient StoriesLymphoma
Rex Jones found a unique way to keep his mood upbeat and spread good vibes to others during his chemotherapy for lymphoma.
Silver Linings
Patient StoriesLymphoma
Stacey Roselle looked for the “silver linings” when a diagnosis of non-Hodgkin lymphoma brought her face-to-face with unexpected reactions to her illness.
Page 1 of 5
Results 1 - 10 of 50

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country